Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
India’s Startup Funding Continues to Decline, While Over 50 Get Recognised in One Day.
New Delhi: India’s startup ecosystem is expanding at an unprecedented pace, with over 50 startups being recognised every day, according to Union Commerce and Industry Minister Piyush Goyal. The milestone underscores the...





Discussion about this post